Covid vaccine: Single-dose Sputnik Light gets DCGI nod for emergency use

Sputnik V is a heterogeneous vaccine which uses two different components in its two doses

Sputnik
Test tubes are seen in front of a displayed Sputnik V logo in this illustration (Photo: Reuters)
Sohini Das Mumbai
1 min read Last Updated : Feb 06 2022 | 11:22 PM IST
India has got its ninth Covid vaccine as the country’s drug regulator approved the use of Sputnik Light or the single dose regime of Sputnik V for use in the country.

Union health minister Mansukh Mandaviya said in a tweet on Sunday that the Drugs Controller General of India (DCGI) granted emergency use permission to single-dose Sputnik Light Covid-19 vaccine in India.

“This is the 9th #COVID19 vaccine in the country. This will further strengthen the nation’s collective fight against the pandemic,” the minister said in his tweet.

Dr Reddy's Laboratories ( DRL) is the marketing partner for Sputnik vaccines from Russia here. There are several Indian manufacturing partners for the vaccine, including Serum Institute of India, Panacea Biotec and Hetero, among others.

Sputnik V is a heterogeneous vaccine that uses two different components in its two doses — Ad26 and Ad5. Sputnik Light is the first dose of Sputnik V.

So far, 1.2 million Sputnik V vaccines have been administered to Indians, according to Cowin data.

The vaccine is available in the private channel only, and the Centre has not procured it for free vaccination.


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirus VaccineVaccineVaccination

Next Story